Head-To-Head Analysis: XenoPort (XNPT) versus The Competition

XenoPort (NASDAQ: XNPT) is one of 106 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare XenoPort to similar businesses based on the strength of its analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Institutional and Insider Ownership

43.3% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.7% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares XenoPort and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
XenoPort -103.12% -414.36% -37.19%
XenoPort Competitors -2,399.51% -66.70% -7.72%

Analyst Recommendations

This is a summary of current ratings and target prices for XenoPort and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XenoPort 0 0 0 0 N/A
XenoPort Competitors 1000 3993 6988 190 2.52

As a group, “Pharmaceuticals” companies have a potential upside of 25.89%.

Valuation & Earnings

This table compares XenoPort and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
XenoPort N/A N/A N/A
XenoPort Competitors $8.54 billion $861.67 million 143.09

XenoPort’s competitors have higher revenue and earnings than XenoPort. XenoPort is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


XenoPort competitors beat XenoPort on 6 of the 7 factors compared.

XenoPort Company Profile

XenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company’s segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson’s disease.

Receive News & Ratings for XenoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XenoPort and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply